Skip to content
  • menu secondaire

    • Investors
    • Careers
    • Terms of Use
    • privacy policy
    • Cookie policy
    • Contacts
    • Profile
      • About Transgene
      • Management Team
      • Board of Directors
      • Scientific advisors
      • Corporate governance
      • Ethics & compliance
      • Collaborations
      • Partners
    • Technology
      • Viral-based Immunotherapies
        • Therapeutic Vaccines
        • Oncolytic Viruses
      • myvac Platform
      • Invir.IO Platform
      • Publications and Presentations
    • Portfolio
      • Pipeline
      • TG4050
      • TG4001
      • TG6002
      • TG6050
      • BT-001
      • Clinical trials FAQ
    • Press Releases

    Category: TG4010

    The MVA viral platform for the treatment of cancer and chronic infectious diseases: Clinical experience from four randomized controlled phase II studies

    Poster MVA VIRAL PLATFORM-AACR 2015-JML Jean-Marc Limacher, et al. AACR Annual Meeting, Philadelphia, PA, USA, 18-22 April 2015, Abst. 2498. Download the poster here Poster Presentation

    Published 21 April 2015
    Categorized as 2015, Publication, TG4010

    Transgene Announces New Pre-Clinical Data with TG4010 in Combination with Immune Checkpoint Inhibitors and TG3003 (humanized mAb anti-CD115) to be Presented at AACR

    18032015_AACR 2015 curtain raiser_EN

    Published 19 March 2015
    Categorized as 2015, Press release, TG3003, TG4010

    TG4010 Immunotherapy Combined with First-line Therapy in Advanced Non- Small Cell Lung Cancer (NSCLC). Phase 2b Results of the TIME Study

    Elisabeth Quoix, et al. Journal for Immunotherapy of Cancer, 2014, 2 (suppl. 3), O12 – Download the article Publication

    Published 6 November 2014
    Categorized as 2014, Publication, TG4010

    TIME: A Phase 2b/3 Evaluating TG4010 in Combination with First-line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC). Phase 2b results.

    ESMO 2014-Poster TG4010 TIME Ph 2b Elisabeth Quoix, et al. ESMO 2014 Congress, Madrid, Spain, 26-30 September 2014, Abst. 5152 Download the poster here Poster Presentation

    Published 30 September 2014
    Categorized as 2014, Publication, TG4010

    Transgene Reports Financial Results for First Six Months of 2014 and Provides Update on TG4010

    261_en

    Published 8 September 2014
    Categorized as 2014, Press release, TG4010

    Immunotherapy for non – small – cell lung cancer: current approaches.

    Elisabeth Quoix, et al. Current Respiratory Care Reports, 2014; 3 (1): 19-25 – Download the article Publication

    Published 31 January 2014
    Categorized as 2014, Publication, TG4010

    Therapeutic cancer vaccines in the treatment of non-small cell lung cancer

    Jean-Marc Limacher, et al. Expert Review of Vaccines, 2013; 12(3): 263-270 – Download the article Publication

    Published 12 March 2013
    Categorized as 2013, Publication, TG4010

    Posts navigation

    Newer posts Page 1 … Page 3
    • Investors
    • Careers
    • Terms of Use
    • privacy policy
    • Cookie policy
    • Contacts

    Transgene sa
    400 Boulevard Gonthier d’Andernach - Parc d'Innovation - CS80166
    67405 Illkirch Graffenstaden Cedex - France |
    Tel. : + 33 (0) 3 88 27 91 00

     

    © 2021 Transgene - All rights reserved
    Credits

    This Website uses cookies to provide you with the most relevant experience. By clicking on the "Accept All" button, you agree to the deposit of all cookies on your terminal. You can change your preferences or withdraw your consent at any time by clicking on the "Settings" button.
    More informationSettings Decline all ACCEPT ALL
    Cookies

    Privacy Overview

    This website uses cookies to improve your experience while you browse the website. Of these, cookies categorized as necessary are stored on your browser as they are essential for the functioning of basic functionalities of the website. We also use third-party cookies which advise us to analyze and understand how you use this website. These cookies will only be stored in your browser with your consent. You also have the option of deactivating these cookies. But disabling some of these cookies may affect your browsing experience.
    Necessary
    Always Enabled
    Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously. Analytical cookies used to understand how visitors interact with the website.
    Functional (video)
    Functional cookies help to perform certain functions such as sharing website content on social media platforms, collecting feedback and other third-party functionality.
    Third-party application cookies (twitter)
    Cookies déposés par des sociétés autres que Transgene. Ces cookies sont susceptibles de transmettre aux sociétés tiers des informations en lien avec les pages consultées. Ces sociétés doivent s’engager à garder ces données confidentielles dans le cadre de la loi informatique et libertés (6 janvier 1978).
    Save & Accept
    Powered by CookieYes Logo